CN109689664B - 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物 - Google Patents
作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物 Download PDFInfo
- Publication number
- CN109689664B CN109689664B CN201780056459.5A CN201780056459A CN109689664B CN 109689664 B CN109689664 B CN 109689664B CN 201780056459 A CN201780056459 A CN 201780056459A CN 109689664 B CN109689664 B CN 109689664B
- Authority
- CN
- China
- Prior art keywords
- thiazol
- methoxy
- methylquinoxalin
- methyl
- carbamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362121P | 2016-07-14 | 2016-07-14 | |
| US62/362,121 | 2016-07-14 | ||
| PCT/US2017/041880 WO2018013776A1 (en) | 2016-07-14 | 2017-07-13 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109689664A CN109689664A (zh) | 2019-04-26 |
| CN109689664B true CN109689664B (zh) | 2022-04-15 |
Family
ID=59384259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780056459.5A Active CN109689664B (zh) | 2016-07-14 | 2017-07-13 | 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190315774A1 (es) |
| EP (1) | EP3484894B1 (es) |
| JP (1) | JP6903732B2 (es) |
| KR (1) | KR102468661B1 (es) |
| CN (1) | CN109689664B (es) |
| ES (1) | ES2823127T3 (es) |
| WO (1) | WO2018013776A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102494647B1 (ko) | 2016-07-14 | 2023-01-31 | 브리스톨-마이어스 스큅 컴퍼니 | 비시클릭 헤테로아릴 치환된 화합물 |
| JP7102388B2 (ja) | 2016-07-14 | 2022-07-19 | ブリストル－マイヤーズ スクイブ カンパニー | 単環式ヘテロアリール置換化合物 |
| CN111440146B (zh) * | 2020-05-15 | 2022-10-21 | 中国药科大学 | 一种具有par4拮抗活性的苯并三嗪类化合物及其应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982001706A1 (en) * | 1980-11-11 | 1982-05-27 | Tominaga Michiaki | Carbostyril compounds,composition containing same,and process for their preparation |
| EP0534443A1 (en) * | 1991-09-26 | 1993-03-31 | Mitsubishi Chemical Corporation | 3,6-Disubstituted pyridazine derivatives |
| WO2013163241A1 (en) * | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| WO2015077550A1 (en) * | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| WO2017019828A1 (en) * | 2015-07-30 | 2017-02-02 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| WO2018013770A1 (en) * | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| WO2018013774A1 (en) * | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| US6387942B2 (en) * | 2000-06-19 | 2002-05-14 | Yung Shin Pharmaceutical Ind. Co. Ltd | Method of treating disorders related to protease-activated receptors-induced cell activation |
| EP1348701A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors |
| RU2355687C2 (ru) | 2003-08-01 | 2009-05-20 | Дженелэбс Текнолоджиз, Инк | Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae |
| US20050272784A1 (en) | 2004-05-07 | 2005-12-08 | Xiaobing Li | Inhibitors of bacterial Type III protein secretion systems |
| RU2007107177A (ru) | 2004-07-28 | 2008-09-10 | Айрм Ллк (Bm) | Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов |
| CN101103026A (zh) | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | 用于治疗病毒感染的吲哚衍生物 |
| WO2007149395A2 (en) | 2006-06-20 | 2007-12-27 | Amphora Discovery Corporation | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer |
| CN101479249B (zh) | 2006-06-29 | 2012-10-10 | 霍夫曼-拉罗奇有限公司 | 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂 |
| WO2008073451A2 (en) | 2006-12-11 | 2008-06-19 | Sirtris Pharmaceuticals, Inc. | Benzoimidazole derivatives as sirtuin (sir) modulating compounds |
| CN101983384A (zh) | 2007-11-30 | 2011-03-02 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
| JP5425891B2 (ja) | 2008-05-01 | 2014-02-26 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節薬としてのキノリンおよび関連する類似体 |
| JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| CA2731498A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| WO2012154888A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Compounds for treating protein folding disorders |
| US9394297B2 (en) | 2012-02-28 | 2016-07-19 | Amgen Inc. | Amides as pim inhibitors |
| CN104583218B (zh) | 2012-04-26 | 2018-04-24 | 百时美施贵宝公司 | 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物 |
| JP6181744B2 (ja) | 2012-04-26 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾール誘導体 |
| US9617279B1 (en) | 2014-06-24 | 2017-04-11 | Bristol-Myers Squibb Company | Imidazooxadiazole compounds |
| US9598419B1 (en) | 2014-06-24 | 2017-03-21 | Universite De Montreal | Imidazotriazine and imidazodiazine compounds |
| US10214544B2 (en) | 2015-02-26 | 2019-02-26 | Universite De Montreal | Imidazopyridazine and imidazothiadiazole compounds |
| WO2016138199A1 (en) | 2015-02-26 | 2016-09-01 | Bristol-Myers Squibb Company | Benzothiazole and benzothiophne compounds |
| JP7102388B2 (ja) | 2016-07-14 | 2022-07-19 | ブリストル－マイヤーズ スクイブ カンパニー | 単環式ヘテロアリール置換化合物 |
-
2017
- 2017-07-13 ES ES17742926T patent/ES2823127T3/es active Active
- 2017-07-13 KR KR1020197004282A patent/KR102468661B1/ko active IP Right Grant
- 2017-07-13 JP JP2019501630A patent/JP6903732B2/ja active Active
- 2017-07-13 US US16/317,258 patent/US20190315774A1/en not_active Abandoned
- 2017-07-13 WO PCT/US2017/041880 patent/WO2018013776A1/en unknown
- 2017-07-13 EP EP17742926.3A patent/EP3484894B1/en active Active
- 2017-07-13 CN CN201780056459.5A patent/CN109689664B/zh active Active
-
2021
- 2021-01-06 US US17/142,288 patent/US11932658B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982001706A1 (en) * | 1980-11-11 | 1982-05-27 | Tominaga Michiaki | Carbostyril compounds,composition containing same,and process for their preparation |
| EP0534443A1 (en) * | 1991-09-26 | 1993-03-31 | Mitsubishi Chemical Corporation | 3,6-Disubstituted pyridazine derivatives |
| WO2013163241A1 (en) * | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| WO2015077550A1 (en) * | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| WO2017019828A1 (en) * | 2015-07-30 | 2017-02-02 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| WO2018013770A1 (en) * | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| WO2018013774A1 (en) * | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
Non-Patent Citations (2)
| Title |
|---|
| Studies on the Chemical constituents of Rutaceous Plants.XXXVI.Synthesis of Ethyl Isodecarine;HISASHI ISHII et al.;《Chem. Phem. Bull》;19771231;第514-519页 * |
| Substituted indoles as selective protease activated receptor 4 (PAR-4)antagonists: Discovery and SAR of ML354;Wandong Wen et al.;《Bioorganic & Medicinal Chemistry Letters》;20140815;第4708-4713页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190026906A (ko) | 2019-03-13 |
| ES2823127T3 (es) | 2021-05-06 |
| EP3484894B1 (en) | 2020-08-19 |
| WO2018013776A1 (en) | 2018-01-18 |
| KR102468661B1 (ko) | 2022-11-17 |
| CN109689664A (zh) | 2019-04-26 |
| EP3484894A1 (en) | 2019-05-22 |
| US20190315774A1 (en) | 2019-10-17 |
| JP6903732B2 (ja) | 2021-07-14 |
| US20210188877A1 (en) | 2021-06-24 |
| JP2019524732A (ja) | 2019-09-05 |
| US11932658B2 (en) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114615981B (zh) | Kras g12d抑制剂 | |
| CN103562210B (zh) | 对pI3K 110δ具有选择性的苯并氧氮杂*化合物及使用方法 | |
| CN109689647B (zh) | 二环杂芳基取代的化合物 | |
| CN109689649B (zh) | 经二环杂芳基取代的化合物 | |
| CN105916855B (zh) | 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物 | |
| CN102459272B (zh) | 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法 | |
| CN102356081B (zh) | 减少β-淀粉状蛋白生成的双环化合物 | |
| JP2020518601A (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| WO2020221239A1 (zh) | 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途 | |
| CN115551867A (zh) | 稠合三环类化合物、其药物组合物及用途 | |
| TW201831471A (zh) | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 | |
| CN107709322B (zh) | 作为抗癌剂的三环化合物 | |
| US11932658B2 (en) | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | |
| TW201609725A (zh) | 作為抗癌劑之新穎三環化合物 | |
| US20240018161A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| EP4225764A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| JP6954920B2 (ja) | ブロモドメイン阻害薬としてのベンゾ［ｂ］フラン | |
| WO2023138583A1 (zh) | 杂环类化合物、药物组合物及其应用 | |
| JP2021527102A (ja) | ガレクチン−３抑制剤を模したテトラヒドロピラン系チオ二糖類 | |
| TW201615644A (zh) | 作為人類免疫缺乏病毒複製之抑制劑的吡唑并嘧啶巨環化合物 | |
| CN109689642B (zh) | 经单环杂芳基取代的化合物 | |
| CN114980975A (zh) | 二氢环戊二烯并异喹啉磺酰胺衍生物 | |
| WO2022166796A1 (zh) | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 | |
| CN116640156A (zh) | Ripk1抑制剂 | |
| CN116731016A (zh) | 作为iap拮抗剂的三环杂环化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |